PolyPeptide posted a first half loss of 26.5 million euros compared to a loss of 11.4 million euros, prior year. Basic loss per share was 0.80 euros compared to a loss of 0.35 euros. EBITDA was 4.4 million euros, up 54.6%. Revenue was 167.1 million euros, up 23.7% from last year, or up 23.3% at constant currency rates, driven mainly by growth in metabolic therapeutics.
The company revised full-year guidance for 2025 towards the upper end of the range, and confirmed its mid-term outlook. For 2025, the company now expects revenue growth of 13-20% at constant currency rates, with an EBITDA margin in the high single-digit/low double-digit range.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.